Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

11.42 -0.69 (-5.70%)

Streaming Delayed Price Updated: 11:54 AM EST, Jan 28, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	713,621
Open	12.02
Bid (Size)	11.40 (300)
Ask (Size)	11.44 (100)
Prev. Close	12.11
Today's Range	10.97 - 12.12
52wk Range	3.895 - 14.93
Shares Outstanding	54,532,614
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

January 12, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

Performance

YTD	+39.8%	+39.8%
1 Month	+38.4%	+38.4%
3 Month	-15.0%	-15.0%
6 Month	+3.4%	+3.4%
1 Year	+5.4%	+5.4%

More News

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

December 04, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

December 03, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

December 01, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

November 24, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

November 20, 2025

Via Benzinga

This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

November 20, 2025

Via Benzinga

This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 20, 2025

Via Benzinga

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 14, 2025

Via Benzinga

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

November 13, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

November 13, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

November 06, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

November 04, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

October 27, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 05, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

August 27, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

August 18, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC Pharmaceuticals Inc (NASDAQ:ORIC) Reports Q2 2025 Wider Loss but Extends Cash Runway with Strategic Restructuring ↗

August 12, 2025

Via Chartmill

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

August 12, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

Frequently Asked Questions

Is Oric Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Oric Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Oric Pharmaceuticals, Inc. - Common Stock trade on?

Oric Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock is ORIC on the Nasdaq Stock Market

What is the current price of Oric Pharmaceuticals, Inc. - Common Stock?

The current price of Oric Pharmaceuticals, Inc. - Common Stock is 11.42

When was Oric Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Oric Pharmaceuticals, Inc. - Common Stock was at 01/28/26 11:54 AM ET

What is the market capitalization of Oric Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Oric Pharmaceuticals, Inc. - Common Stock is 622.76M

How many shares of Oric Pharmaceuticals, Inc. - Common Stock are outstanding?

Oric Pharmaceuticals, Inc. - Common Stock has 623M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.